China approves coronavirus drug for limited use

  • China approves coronavirus drug for limited use

China approves coronavirus drug for limited use

Other leading vaccine candidates are the USA pharma giant Pfizer, who is working with Germany's BioNTech on developing a candidate now in phase two trials, and also Oxford University/AstraZeneca in the United Kingdom that has a $1.2 billion U.S. investment attached.

Measuring that with the first proven vaccine will "really help us understand for all the other vaccines in development, do they also have a chance?" said Oxford University lead researcher Sarah Gilbert.

More than half of the 17 candidate vaccines identified by the World Health Organization (WHO) as being at the clinical evaluation stage involve Chinese companies or institutes.

Beijing, June 28 (SocialNews.XYZ) A Covid-19 vaccine candidate developed by a Beijing unit of China National Biotec Group (CNBG) has shown positive results in early human trials, the company said on Sunday. The vaccine candidate was developed jointly by CanSino and a research institute at the Academy of Military Science (AMS). Trials started on 17 March.

Biotech firm CanSino Biologics said that it has received approvals from the Chinese Central Military Commission for use of its Ad5-nCoV as Covid-19 vaccine by the military for a period of one year, Reuters reported on Monday. In their place, a piece of DNA that codes for the coronavirus spike protein is inserted. To stop it replicating, the virus is made inactive by removing certain genes.

Another vaccine made by the NIH and Moderna Inc. simply injects a part of the coronavirus genetic code that instructs the body to produce copies of harmless spikes that the immune system learns to recognize.

On April 12, the vaccine obtained the world's first clinical trial approval, and phase one and two clinical trials were then launched in Wuzhi county of Henan province.

It was not clear how widely it would be used within China's enormous military forces, and the ministry of defence did not reply to an AFP request for further information.

The Phase 1 and 2 clinical trials of the CanSino's vaccine candidate showed it has the potential to prevent diseases caused by the coronavirus, which has killed half a million people globally, but its commercial success can not be guaranteed, the company said.

None has yet been approved for commercial use.

According to medical journal The Lancet there have already been more than 1,000 clinical trials on dozens of pharmaceutical treatments for the virus but no effective medical intervention has yet been found.